These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23169967)

  • 1. 2009 Pandemic influenza A virus subtype H1N1 vaccination in Africa--successes and challenges.
    Mihigo R; Torrealba CV; Coninx K; Nshimirimana D; Kieny MP; Carrasco P; Hedman L; Widdowson MA
    J Infect Dis; 2012 Dec; 206 Suppl 1():S22-8. PubMed ID: 23169967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines against influenza A (H1N1) pandemic.
    Valdespino-Gomez JL; Garcia-Garcia L; de León-Rosales SP
    Arch Med Res; 2009 Nov; 40(8):693-704. PubMed ID: 20304259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pandemic influenza A(H1N1)pdm09 improves vaccination routine in subsequent years: a cohort study from 2009 to 2011.
    Tacken MA; Jansen B; Mulder J; Visscher S; Heijnen ML; Campbell SM; Braspenning JC
    Vaccine; 2013 Jan; 31(6):900-5. PubMed ID: 23246546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pandemic influenza A (H1N1)v vaccination status and factors affecting vaccination: Ankara and Diyarbakır 2009 data from Turkey].
    Ertek M; Sevencan F; Kalaycıoğlu H; Gözalan A; Simşek C; Culha G; Dorman V; Ozlü A; Arıkan F; Aktaş D; Akın L; Korukluoğlu G; Sevindi DF
    Mikrobiyol Bul; 2011 Oct; 45(4):684-96. PubMed ID: 22090299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Events supposedly attributable to vaccination or immunization during pandemic influenza A (H1N1) vaccination campaigns in Latin America and the Caribbean.
    Ropero-Álvarez AM; Whittembury A; Bravo-Alcántara P; Kurtis HJ; Danovaro-Holliday MC; Velandia-González M
    Vaccine; 2015 Jan; 33(1):187-92. PubMed ID: 25444798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uptake and effectiveness of monovalent influenza A (H1N1) pandemic 2009 vaccine among healthcare personnel in Kenya, 2010.
    Njuguna H; Ahmed J; Oria PA; Arunga G; Williamson J; Kosgey A; Muthoka P; Mott JA; Breiman RF; Katz MA
    Vaccine; 2013 Sep; 31(41):4662-7. PubMed ID: 23859843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population and risk group uptake of H1N1 influenza vaccine in mainland France 2009-2010: results of a national vaccination campaign.
    Bone A; Guthmann JP; Nicolau J; Lévy-Bruhl D
    Vaccine; 2010 Nov; 28(51):8157-61. PubMed ID: 20937310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seasonal influenza vaccination status among children with laboratory evidence of pandemic H1N1 infection.
    Nelson CA; France EK; Shetterly SM; Glanz JM
    Pediatr Infect Dis J; 2011 Jul; 30(7):562-5. PubMed ID: 21248657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns.
    Wijnans L; Lecomte C; de Vries C; Weibel D; Sammon C; Hviid A; Svanström H; Mølgaard-Nielsen D; Heijbel H; Dahlström LA; Hallgren J; Sparen P; Jennum P; Mosseveld M; Schuemie M; van der Maas N; Partinen M; Romio S; Trotta F; Santuccio C; Menna A; Plazzi G; Moghadam KK; Ferro S; Lammers GJ; Overeem S; Johansen K; Kramarz P; Bonhoeffer J; Sturkenboom MC
    Vaccine; 2013 Feb; 31(8):1246-54. PubMed ID: 23246544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for 2009 pandemic influenza A(H1N1) vaccination.
    Chlibek R; Anca I; André F; Bakir M; Ivaskeviciene I; Mangarov A; Mészner Z; Perenovska P; Prymula R; Richter D; Salman N; Simurka P; Tamm E; Toplak N; Usonis V
    Vaccine; 2010 May; 28(22):3758-66. PubMed ID: 20380902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011.
    Girard MP; Katz JM; Pervikov Y; Hombach J; Tam JS
    Vaccine; 2011 Oct; 29(44):7579-86. PubMed ID: 21856358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of the pandemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: population-based case-control study.
    Mahmud S; Hammond G; Elliott L; Hilderman T; Kurbis C; Caetano P; Van Caeseele P; Kettner J; Dawood M
    Vaccine; 2011 Oct; 29(45):7975-81. PubMed ID: 21884747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coverage and predictors of vaccination against 2009 pandemic H1N1 influenza in Madrid, Spain.
    Rodríguez-Rieiro C; Esteban-Vasallo MD; Domínguez-Berjón MF; Astray-Mochales J; Iniesta-Fornies D; Barranco-Ordoñez D; Cameno-Heras M; Jiménez-García R
    Vaccine; 2011 Feb; 29(6):1332-8. PubMed ID: 21182996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pandemic influenza vaccination: lessons learned from Latin America and the Caribbean.
    Ropero-Álvarez AM; Whittembury A; Kurtis HJ; dos Santos T; Danovaro-Holliday MC; Ruiz-Matus C
    Vaccine; 2012 Jan; 30(5):916-21. PubMed ID: 22155136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009-10.
    Emborg HD; Krause TG; Hviid A; Simonsen J; Mølbak K
    BMJ; 2011 Jan; 344():d7901. PubMed ID: 22277542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
    Hakim H; Allison KJ; Van De Velde LA; Li Y; Flynn PM; McCullers JA
    Vaccine; 2012 Jan; 30(5):879-85. PubMed ID: 22155630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation.
    Baguelin M; Hoek AJ; Jit M; Flasche S; White PJ; Edmunds WJ
    Vaccine; 2010 Mar; 28(12):2370-84. PubMed ID: 20096762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
    Gilca V; De Serres G; Hamelin ME; Boivin G; Ouakki M; Boulianne N; Sauvageau C; Dionne M; Gilca R; Skowronski D
    Vaccine; 2011 Dec; 30(1):35-41. PubMed ID: 22063386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination coverage with seasonal and pandemic influenza vaccines in children in France, 2009-2010 season.
    Weil-Olivier C; Lina B
    Vaccine; 2011 Sep; 29(40):7075-9. PubMed ID: 21777639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.